93
Participants
Start Date
January 4, 2024
Primary Completion Date
August 21, 2025
Study Completion Date
August 21, 2025
Estradiol
Oral 17-β estradiol 2 mg once daily will be initiated at study entry. At weeks 4, 12, 24, and 36, study clinicians may titrate 17-β estradiol in 2 mg increments to achieve the desired participant goals and target hormone concentrations, as measured locally at each visit.
Barranco CRS (11301), Lima
Weill Cornell Uptown CRS (site 7803), New York
Thai Red Cross AIDS Research Centre (TRC-ARC) CRS (31802), Bangkok
Nutrición-Mexico CRS (32078), Mexico City
Whitman-Walker Institute, Inc. CRS (31791), Washington D.C.
Johns Hopkins University CRS (201), Baltimore
Greensboro CRS (3203), Greensboro
The Ponce de Leon Center CRS (5802), Atlanta
Vanderbilt Therapeutics CRS, Nashville
Case CRS (2501), Cleveland
Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS (31784), Chiang Mai
Houston AIDS Research Team CRS (31473), Houston
University of Colorado Hospital CRS (6101), Aurora
UCSD Antiviral Research Center CRS (701), San Diego
University of California, San Francisco HIV/AIDS CRS (801), San Francisco
Washington University Therapeutics (WT) CRS (2101), St Louis
New Jersey Medical School Clinical Research Center CRS (31786), Newark
Chapel Hill CRS (3201), Chapel Hill
National Institute of Allergy and Infectious Diseases (NIAID)
NIH